Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19344
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKaramanakos, P. N.en
dc.contributor.authorPappas, P.en
dc.contributor.authorBoumba, V. A.en
dc.contributor.authorThomas, C.en
dc.contributor.authorMalamas, M.en
dc.contributor.authorVougiouklakis, T.en
dc.contributor.authorMarselos, M.en
dc.date.accessioned2015-11-24T18:59:07Z-
dc.date.available2015-11-24T18:59:07Z-
dc.identifier.issn1091-5818-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19344-
dc.rightsDefault Licence-
dc.subject3,4-Dihydroxyphenylacetic Acid/metabolismen
dc.subjectAcetaldehyde/metabolismen
dc.subjectAlcohol Dehydrogenase/metabolismen
dc.subjectAldehyde Dehydrogenase/metabolismen
dc.subjectAnimalsen
dc.subjectBiogenic Monoamines/*metabolismen
dc.subjectChloramphenicol/administration & dosage/pharmacologyen
dc.subjectDisulfiram/administration & dosage/*pharmacology/standardsen
dc.subjectDopamine/metabolismen
dc.subjectDopamine beta-Hydroxylase/antagonists & inhibitorsen
dc.subjectEthanol/*metabolismen
dc.subjectFurazolidone/administration & dosage/pharmacologyen
dc.subjectHomovanillic Acid/metabolismen
dc.subjectHydroxyindoleacetic Acid/metabolismen
dc.subjectHypothalamus/chemistry/drug effects/metabolismen
dc.subjectIntubation, Gastrointestinalen
dc.subjectLiver/*drug effects/metabolismen
dc.subjectMaleen
dc.subjectMesencephalon/chemistry/drug effects/metabolismen
dc.subjectMetronidazole/administration & dosage/pharmacologyen
dc.subjectNorepinephrine/metabolismen
dc.subjectQuinacrine/administration & dosage/pharmacologyen
dc.subjectRatsen
dc.subjectRats, Wistaren
dc.subjectSerotonin/metabolismen
dc.titlePharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoaminesen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1080/10915810701583010-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17963129-
heal.identifier.secondaryhttp://ijt.sagepub.com/content/26/5/423-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2007-
heal.abstractSeveral pharmaceutical agents produce ethanol intolerance, which is often depicted as disulfiram-like reaction. As in the case with disulfiram, the underlying mechanism is believed to be the accumulation of acetaldehyde in the blood, due to inhibition of the hepatic aldehyde dehydrogenases. In the present study, chloramphenicol, furazolidone, metronidazole, and quinacrine, which are reported to produce a disulfiram-like reaction, as well as disulfiram, were administered to Wistar rats and the hepatic activities of alcohol and aldehyde dehydrogenases (1A1 and 2) were determined. The expression of aldehyde dehydrogenase 2 was further assessed by Western blot analysis, while the levels of brain monoamines were also analyzed. Finally, blood acetaldehyde was evaluated after ethanol administration in rats pretreated with disulfiram, chloramphenicol, or quinacrine. The activity of aldehyde dehydrogenase 2 was inhibited by disulfiram, chloramphenicol, and furazolidone, but not by metronidazole or quinacrine. In addition, although well known for metronidazole, quinacrine also did not increase blood acetaldehyde after ethanol administration. The protein expression of aldehyde dehydrogenase 2 was not affected at all. Interestingly, all substances used, except disulfiram, increased the levels of brain serotonin. According to our findings, metronidazole and quinacrine do not produce a typical disulfiram-like reaction, because they do not inhibit hepatic aldehyde dehydrogenase nor increase blood acetaldehyde. Moreover, all tested agents share the common property to enhance brain serotonin, whereas a respective effect of ethanol is well established. Therefore, the ethanol intolerance produced by these agents, either aldehyde dehydrogenase is inhibited or not, could be the result of a "toxic serotonin syndrome," as in the case of the concomitant use of serotonin-active medications.en
heal.journalNameInt J Toxicolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons